↓ Skip to main content

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment

Overview of attention for article published in Blood Cancer Journal, February 2021
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#1 of 1,043)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
51 news outlets
twitter
13 tweeters

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
36 Mendeley